These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14720058)

  • 1. Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics.
    Chiu LM; Amsden GW
    Am J Respir Med; 2002; 1(3):201-9. PubMed ID: 14720058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.
    Scaglione F; Paraboni L
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):479-90. PubMed ID: 16771624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of pharmacokinetics and pharmacodynamics: does the dose matter?
    MacGowan AP
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S238-9. PubMed ID: 11524725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens.
    Schaper KJ; Schubert S; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolides: pharmacokinetics and pharmacodynamics.
    Van Bambeke F; Tulkens PM
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S17-23. PubMed ID: 11574190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering antibacterials to the lungs: considerations for optimizing outcomes.
    Cazzola M; Blasi F; Terzano C; Matera MG; Marsico SA
    Am J Respir Med; 2002; 1(4):261-72. PubMed ID: 14720046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacodynamic and pharmacokinetic of antibiotics for treatment of skin and soft tissue infections].
    Mazzei T; Novelli A; Arrigucci S
    Infez Med; 2009 Sep; 17 Suppl 4():37-57. PubMed ID: 20428019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New dosing strategies for antibacterial agents in the neonate.
    de Hoog M; Mouton JW; van den Anker JN
    Semin Fetal Neonatal Med; 2005 Apr; 10(2):185-94. PubMed ID: 15701583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal macrolide resistance--myth or reality?
    Amsden GW
    J Antimicrob Chemother; 1999 Jul; 44(1):1-6. PubMed ID: 10459803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.
    Nicolau DP
    Infection; 2001 Dec; 29 Suppl 2():11-5. PubMed ID: 11785851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
    Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
    Touw DJ; Vinks AA; Mouton JW; Horrevorts AM
    Clin Pharmacokinet; 1998 Dec; 35(6):437-59. PubMed ID: 9884816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.